-transparent.png){kind=logo}
It has been suggested that neuropeptide Y (NPY) is involved in the pathophysiology of depression. Plasma peptide-rich fraction from patients with major depressive disorder and control subjects was eluted with high performance liquid chromatography (HPLC), followed by radioimmunoassay of NPY. The screening patterns of the NPY-like immunoreactivity in 50 fractions eluted by HPLC from the plasma peptide-rich fraction were different between the two groups. The values of NPY in the 16 controls and the 14 patients were 427 +/- 38 and 310 +/- 27 fmol/ml plasma (P < 0.05), respectively. These results suggest that impaired metabolism of plasma NPY and the reduced plasma NPY in patients with major depressive disorder could be involved in the pathogenesis or pathophysiology of major depressive disorder.
H Hashimoto, and
H Onishi, and
S Koide, and
T Kai, and
S Yamagami
December 2020,
The international journal of neuropsychopharmacology,
H Hashimoto, and
H Onishi, and
S Koide, and
T Kai, and
S Yamagami
January 1996,
The American journal of psychiatry,
H Hashimoto, and
H Onishi, and
S Koide, and
T Kai, and
S Yamagami
February 2017,
Psychiatric genetics,
H Hashimoto, and
H Onishi, and
S Koide, and
T Kai, and
S Yamagami
June 2006,
Brain research,
H Hashimoto, and
H Onishi, and
S Koide, and
T Kai, and
S Yamagami
September 2012,
Psychoneuroendocrinology,
H Hashimoto, and
H Onishi, and
S Koide, and
T Kai, and
S Yamagami
March 2023,
Neuropsychopharmacology reports,
H Hashimoto, and
H Onishi, and
S Koide, and
T Kai, and
S Yamagami
May 2018,
Psychiatry and clinical neurosciences,
H Hashimoto, and
H Onishi, and
S Koide, and
T Kai, and
S Yamagami
January 2013,
PloS one,
H Hashimoto, and
H Onishi, and
S Koide, and
T Kai, and
S Yamagami
March 2016,
CNS neuroscience & therapeutics,
H Hashimoto, and
H Onishi, and
S Koide, and
T Kai, and
S Yamagami
January 2017,
Frontiers in psychiatry,
